Biomarker validation is still the bottleneck in biomarker research

Journal of Internal Medicine

Volumn 272, Issue 6, 2012, Pages 620-620

  Diamandis, E P ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AFFINITY CHROMATOGRAPHY; ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; LETTER; PRIORITY JOURNAL; SELECTED REACTION MONITORING ASSAY;

EID: 84869871560     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02579.x     Document Type: Letter

References (6)

1. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2012; 271: 111-21.
2. Drabovich AP, Pavlou MP, Dimitromanolakis A, Diamandis EP. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol Cell Proteomics 2012; 11, April 25 [Epub ahead of print].
3. Drabovich AP, Jarvi K, Diamandis EP. Verification of male infertility biomarkers in seminal plasma by multiplex selected reaction monitoring assay. Mol Cell Proteomics 2011; 10: M110.004127.
4. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG/L. J Urol 1997; 157: 913-8.
5. Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffrey DA, Diamandis EP "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 2008; 7: 640-7.
6. Lopez MF, Rezai T, Sarracino DA et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010; 56: 281-90.